The approval was supported by results from the IMbrave150 trial (). This phase 3 trial enrolled 501 patients with hepatocellular carcinoma who were randomized to receive either sorafenib or atezolizumab plus bevacizumab.
The median overall survival was not reached in patients who received atezolizumab plus bevacizumab, but it was 13.2 months in patients who received sorafenib (hazard ratio, 0.58; 95% confidence interval, 0.42-0.79; P = .0006). The median progression-free survival was 6.8 months in patients who received atezolizumab plus bevacizumab and 4.3 months for those who received sorafenib.
The most common adverse events seen in the atezolizumab-bevacizumab arm were hypertension, fatigue, and proteinuria.
The recommendeddose is 1,200 mg, followed by 15 mg/kg on the same day every 3 weeks.
The FDA collaborated with regulatory agencies from Canada, Australia, and Singapore on the review of the atezolizumab application, as part of. The FDA approved the application ahead of schedule. It is still under review for the other agencies.